Competitive landscape
Drugs aimed at the same indication, from approved to preclinical.
1 drug for “Non Small Cell Lung Cancer (Squamous or Non Squamous)”
Phase 2/3 1
- EIK1001Eikon Therapeutics, Inc.Non Small Cell Lung Cancer (Squamous or Non Squamous)
Drugs whose recorded indications name this term, by development stage. Indications come from registries and labels, so a drug can appear under related terms.